secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001157523-23-000822
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Therapeutics reports Q1 2023 net loss of $22.8M; cash at $328M; advancing EDG-5506 and EDG-7500 trials
--------------------------------------------------------------------------------

- Net loss of $22.8M ($0.36 per share) vs $19.4M in prior quarter; R&D spend rose to $19.9M.
- Cash, cash equivalents and marketable securities of $328M as of March 31, 2023.
- Advancing Phase 2 CANYON (BMD) and LYNX (DMD) trials for EDG-5506; interim DMD data expected Q4 2023.
- IND-enabling studies for EDG-7500 (HCM) ongoing; Phase 1 start expected in 2H2023.
- Plan to add registration-enabling cohort in CANYON in 2H2023; 12-month ARCH data expected Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000115752323000822/0001157523-23-000822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000115752323000822/a53398173.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer